Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Subbu Nambi
GUGG

Subbu Nambi

Guggenheim
Wall Street Analyst
★★★★★
#172
on 13Foresight · ranked by our own returns
69%
Success Rate
+16.3%
Average Return
50 of 72 calls profitable · -175.9% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 69% of Subbu Nambi's ratings turned a profit when each position was held for 1 year — averaging +16.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

118 Buy 6 Hold 0 Sell
Subbu's Stock Coverage 29 ratings · 2026-11-15
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
ILMN
Illumina
 Oct 29, 2026 BUY Strong Buy
-10.1% avg upside
32 analysts
$305.00
29.22% Upside
 -28.6% ·
NEOG
Neogen
 Oct 19, 2026 BUY Strong Buy
+105.6% avg upside
6 analysts
$14.00
18.39% Upside
 +0.3% ·
TEM
Tempus AI, Inc. Class A
 Oct 01, 2026 BUY Buy
-0.3% avg upside
25 analysts
$92.00
27.37% Upside
 -6.4% ·
GRAL
GRAIL Inc
 Oct 01, 2026 BUY Buy
-18.5% avg upside
9 analysts
$155.00
8.01% Upside
 -8.5% ·
WGS
GeneDx Holdings
 Oct 01, 2026 BUY Strong Buy
+22.6% avg upside
10 analysts
$83.00
20.23% Upside
 -26.2% ·
ADPT
Adaptive Biotechnologies
 Oct 01, 2026 BUY Strong Buy
+1.9% avg upside
17 analysts
$32.00
20.10% Upside
 +6.1% ·
TWST
Twist Bioscience
 Oct 01, 2026 BUY Strong Buy
-19.2% avg upside
16 analysts
$212.00
38.73% Upside
 -40.6% ·
GH
Guardant Health
 Oct 01, 2026 BUY Strong Buy
-3.1% avg upside
33 analysts
$200.00
11.88% Upside
 -13.2% ·
NTRA
Natera
 Oct 01, 2026 BUY Strong Buy
-13.3% avg upside
28 analysts
$475.00
14.64% Upside
 -21.9% ·
CYRX
CryoPort
 Oct 01, 2026 BUY Strong Buy
-4.2% avg upside
15 analysts
$19.00
9.92% Upside
 +14.6% ·
WAT
Waters
 Oct 01, 2026 BUY Strong Buy
-12.6% avg upside
31 analysts
$490.00
5.88% Upside
 +8.2% ·
BRKR
Bruker
 Oct 01, 2026 BUY Buy
+4.9% avg upside
22 analysts
$72.00
26.10% Upside
 -0.6% ·
DHR
Danaher
 Oct 01, 2026 BUY Strong Buy
-4.4% avg upside
47 analysts
$250.00
7.56% Upside
 +10.0% ·
BLLN
BillionToOne, Inc. Class A
 Oct 01, 2026 BUY Strong Buy
+12.2% avg upside
10 analysts
$128.00
13.01% Upside
 -0.6% ·
FRNM
Freenome Inc
 Aug 20, 2026 BUY Strong Buy
+44.3% avg upside
4 analysts
$21.00
68.28% Upside
 -22.4% ·
VCYT
Veracyte
 Jul 31, 2026 BUY Strong Buy
+4.5% avg upside
19 analysts
$65.00
29.88% Upside
 -47.5% ·
NAUT
Nautilus Biotechnolgy
 Jul 28, 2026 BUY Strong Buy
+321.2% avg upside
5 analysts
$4.00
46.42% Upside
 +98.3% ·
MRVI
Maravai Lifesciences Holdings
 May 11, 2026 HOLD Strong Buy
+99.5% avg upside
18 analysts
 — +59.1% ·
CSTL
Castle Biosciences
 May 07, 2026 BUY Strong Buy
+16.9% avg upside
10 analysts
$47.00
26.39% Upside
 +75.6% ·
PSNL
Personalis
 May 07, 2026 BUY Buy
-6.1% avg upside
11 analysts
$13.00
17.84% Downside
 +162.3% ·
SOPH
SOPHiA GENETICS
 May 06, 2026 BUY Strong Buy
+36.9% avg upside
8 analysts
$7.00
8.18% Downside
 +63.5% ·
RGEN
Repligen
 Feb 24, 2026 HOLD Strong Buy
+1.3% avg upside
25 analysts
 — +32.9% ·
PACB
Pacific Biosciences
 Feb 12, 2026 HOLD Buy
+73.8% avg upside
14 analysts
 — +6.5% ·
NEO
NeoGenomics
 Oct 28, 2025 HOLD Strong Buy
+19.1% avg upside
19 analysts
 — +81.3% ·
RVTY
Revvity
 Oct 27, 2025 HOLD Buy
-19.9% avg upside
25 analysts
 — +67.0% ·
DE:SRT3
Sartorius
 Oct 16, 2025 BUY Strong Buy
-0.2% avg upside
19 analysts
$263.00
9.95% Downside
 +14.7% ·
CAI
Caris Life Sciences, Inc.
 Jul 13, 2025 BUY Strong Buy
-9.5% avg upside
21 analysts
$32.00
6.69% Downside
 -38.5% ·
MYGN
Myriad Genetics
 Apr 08, 2025 HOLD Sell
+159.8% avg upside
24 analysts
 — -38.3% ·
TXG
10x Genomics
 Feb 23, 2025 HOLD Buy
-7.5% avg upside
19 analysts
 — +67.3% ·
🔒 24 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Subbu Nambi — Frequently Asked Questions
How accurate are Subbu Nambi's stock ratings?
Based on the calls 13Foresight could measure, about 69% of Subbu's ratings were profitable over a one-year hold, with an average return of +16.3% per rating, or -175.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Subbu ranked on 13Foresight?
Subbu Nambi is currently ranked #172 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Subbu cover?
Subbu most recently has ratings on ILMN, NEOG, TEM, GRAL, WGS, ADPT, TWST, GH, NTRA, CYRX, WAT, BRKR and 17 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.